This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/
n11http://dx.doi.org/10.7326/

Statements

Subject Item
wd:Q71230816
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в травні 1980 im Mai 1980 veröffentlichter wissenschaftlicher Artikel scientific article published on 01 May 1980 wetenschappelijk artikel artículu científicu espublizáu en mayu de 1980
p:P577
wds:Q71230816-9BCB6DB6-0B6D-475E-BFD4-F5553603FDAB
wdt:P577
1980-05-01T00:00:00Z
p:P407
wds:Q71230816-C4097B59-180C-4A41-B8B2-C7A6D3E0B579
wdt:P407
wd:Q1860
p:P2093
wds:Q71230816-3AD5FDA7-DF36-4AAB-B3CB-0CC40050FBF5 wds:Q71230816-179BDA8F-9F20-4D12-AA37-14D114D70430 wds:Q71230816-B095EB50-E093-47F9-AC79-1A15EDB82E7F wds:Q71230816-92F9AC10-0DC0-4309-9195-AD9C3E4092EC wds:Q71230816-05C44C78-E313-4CC0-87D2-56F43F55CF28
wdt:P2093
W W Parmley B Massie K Chatterjee T A Ports A N Holly
rdfs:label
Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects
skos:prefLabel
Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects
schema:name
Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects
p:P50
wds:Q71230816-2799D8B3-BED4-458B-9E02-E8DDD89B14BA
wdt:P50
wd:Q106622830
p:P1476
wds:Q71230816-5B0FA5CD-0DCE-48A4-88B5-AE0751AB8F35
wdt:P1476
Oral hydralazine in chronic heart failure: sustained beneficial hemodynamic effects
p:P304
wds:Q71230816-C21CCCA3-0374-43EB-9E04-5FFBD9C98A92
wdt:P304
600-604
p:P31
wds:Q71230816-84882D1E-06A3-4CDF-8912-BE65A622AA95
wdt:P31
wd:Q13442814
p:P921
wds:Q71230816-AC7C429D-A8AA-48F8-AC5C-115CD2A40931 wds:Q71230816-11AE6ECE-B526-4221-96B3-5021DF7AAB50 wds:Q71230816-E36947DC-1983-4988-A552-3548297391FC
wdt:P921
wd:Q419987 wd:Q11829287 wd:Q181754
p:P698
wds:Q71230816-380E39F7-906F-4C7B-9F25-D163E1EBE42A
wdtn:P698
n12:7386999
wdt:P698
7386999
p:P1433
wds:Q71230816-828D6D59-3580-47B4-9FCC-AC3B3F40EE9B
wdt:P1433
wd:Q564416
p:P433
wds:Q71230816-31DACE20-A6D7-4D47-9BAD-DA5BA5A5F883
p:P478
wds:Q71230816-B8DA2E7D-D40F-4650-9E1A-6655B6CE0FCF
wdt:P433
5
wdt:P478
92
p:P356
wds:Q71230816-F3340267-7198-4B96-B9BC-12B3A8918483
wdtn:P356
n11:0003-4819-92-5-600
wdt:P356
10.7326/0003-4819-92-5-600